Mendus AB , a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences: LSX.
/PRNewswire/ Serca Pharmaceuticals, a cardioprotection company that is developing 13-M, a novel first-in-class treatment for minimising the tissue damage.